MarginsXMarginsX
Home › Markets › Health Care › ABVX

Abivax SA (ABVX)

ABVX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$83.61
-4.53% on the day
Market cap
$7.3B
Mid cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerABVX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryFrance
IPO year2023
SEC CIK0001956827
SEC industry codePharmaceutical Preparations
Incorporated inFrance

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
38.5 months
516.7M EUR cash at December 31, 2025
Share count, 1 year
+24.0%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed March 23, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-23
Cash and burn516.7M EUR cash; operating cash flow -40.3M EUR a quarter.Report 2025-12-31
Shares outstanding78,536,412 (2025-12-31); 63,347,837 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-07-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPRICEWATERHOUSECOOPERS AUDIT, NEUILLY-SUR-SEINE, FrancePCAOB Form AP 2026-04-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-336.1M EUR-161.1M EUR516.7M EURNo debt tagsNeeds four quarters20-F 2026-03-23
FY 2024
2024-12-31
Not filed-176.2M EUR-154.1M EUR144.2M EURNo debt tagsNeeds four quarters20-F 2026-03-23
FY 2023
2023-12-31
Not filed-147.7M EUR-97.1M EUR251.9M EURNo debt tagsNeeds four quarters20-F 2026-03-23
FY 2022
2022-12-31
Not filed-60.7M EUR-53.9M EUR26.9M EURNo debt tagsNeeds four quarters20-F 2025-03-24
FY 2021
2021-12-31
Not filed-42.5M EUR-45.0M EUR60.7M EURNo debt tagsNeeds four quarters20-F 2024-04-05

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-02
Latest annual report20-F2026-03-23
Latest quarterly / interim6-K2026-09-21

Source: SEC EDGAR submissions feed, 106 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.2%
1 month+1.6%
3 months-27.9%
Year to date-35.1%
1 year-13.2%
From 52-week high-39.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
ALKSAlkermes plc$46.53-1.06%$7.8B
BLTEBelite Bio Inc$162.56-1.09%$6.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier